Want to see TSHA full AI Analyst Report?
TSHA Stock Chart & Stats
$6.43
-$0.08(-4.26%)
At close: 4:00 PM EST
$6.43
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$2.34 - $7.30
Previous CloseN/A
Volume273.02K
Average Volume (3M)3.32M
Market Cap
$2.13B
Enterprise Value$1.29B
Total Cash (Recent Filing)$276.58M
Total Debt (Recent Filing)$17.77M
Price to Earnings (P/E)―
Beta2.63
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding324,861,020
10 Day Avg. Volume3,857,129
30 Day Avg. Volume3,324,583
Financial Highlights & Ratios
PEG Ratio2.91
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue172.68
Enterprise Value/Gross Profit195.73
Enterprise Value/Ebitda-9.99
Forecast
1Y Price Target
$12.70Price Target Upside97.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$818.18K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress And FDA AlignmentDocumented FDA alignment and initiation of a BLA-enabling PPQ materially de-risks the regulatory path over the next 2–6 months. An agreed comparability approach and the option of an interim 6-month review shorten time-to-market if clinical data hold, improving the strategic feasibility of a timely approval.
Solid Cash Runway And Recent Capital RaiseA cash balance plus an expected ~$187M net offering extends runway into 2028, lowering near-term solvency risk. This durable liquidity supports completing BLA-enabling PPQ, pivotal follow-up and commercial planning without immediate financing stress, allowing focus on program execution rather than fundraising in the short-to-medium term.
Robust Clinical Efficacy And Validated Delivery ApproachConsistent, deep functional improvements and favorable safety across Part A and pivotal dosing create a durable clinical value proposition. Preclinical NHP validation of intrathecal delivery and a higher-transduction construct support a scalable, minimally invasive therapy platform that enhances adoption potential and competitive differentiation post-approval.
Bears Say
High Cash Burn And Negative Operating Cash FlowSustained large negative operating and free cash flows indicate the business consumes significant cash to advance programs. Even with current runway, persistent burn requires access to capital if timelines slip, progressively diluting equity and eroding balance sheet strength, constraining long-term flexibility for commercialization investments.
Rapid Expense Ramp Widening Net LossesMaterial increases in R&D and G&A nearly doubled quarterly losses, reflecting BLA and commercial readiness spending. While necessary, this durable rise in fixed-cost base raises the break-even burden and heightens sensitivity to trial, regulatory or launch delays, increasing long-term financing and execution risk.
Manufacturing And Supply‑chain Execution RiskReliance on a single primary manufacturing partner and an uncompleted PPQ creates an operational bottleneck. Delays or comparability issues during PPQ could push regulatory timelines or require costly remedial work; establishing manufacturing redundancy will demand time and capital, making supply chain a structural execution risk.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $2.34 and its highest was $7.30 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $2.13B.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 36 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on May 06, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.023.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 324,861,020 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went up 0.576%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.70 (97.51% Upside)
$12.70 (97.51% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 322.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.62%
12-Months-Change
Fundamentals
Return on Equity
-56.07%
Trailing 12-Months
Asset Growth
117.08%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
TSHA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical, preclinical and regulatory momentum for TSHA-102 — including FDA alignment on a potential expedited pathway, robust Part A efficacy signals (high response rates, multiple developmental milestones and functional gains), initiation of BLA-enabling PPQ, and a solid cash position with runway into 2028. These positives are tempered by materially higher R&D and G&A spending that drove a near-doubling of net loss year-over-year, ongoing uncertainty around whether the FDA will accept a 6-month interim for full approval versus requiring 12-month data, and the need to complete PPQ and validate manufacturing redundancy. Overall, the operational and scientific progress appears to outweigh the financial and timing risks at this stage.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$12.70
▲(97.51% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
2.89% Insiders
8.75% Mutual Funds
0.17% Other Institutional Investors
77.11% Public Companies and
Individual Investors